MCID: CRB138
MIFTS: 43

Core Binding Factor Acute Myeloid Leukemia

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Core Binding Factor Acute Myeloid Leukemia

MalaCards integrated aliases for Core Binding Factor Acute Myeloid Leukemia:

Name: Core Binding Factor Acute Myeloid Leukemia 25 17 71
Cbf Acute Myeloid Leukemia 25
Core-Binding Factor Aml 25
Cbf-Aml 25

Classifications:



External Ids:

UMLS 71 C3839741

Summaries for Core Binding Factor Acute Myeloid Leukemia

Genetics Home Reference : 25 Core binding factor acute myeloid leukemia (CBF-AML) is one form of a cancer of the blood-forming tissue (bone marrow) called acute myeloid leukemia. In normal bone marrow, early blood cells called hematopoietic stem cells develop into several types of blood cells: white blood cells (leukocytes) that protect the body from infection, red blood cells (erythrocytes) that carry oxygen, and blood cell fragments called platelets (thrombocytes) that are involved in blood clotting. In acute myeloid leukemia, the bone marrow makes large numbers of abnormal, immature white blood cells called myeloid blasts. Instead of developing into normal white blood cells, the myeloid blasts develop into cancerous leukemia cells. The large number of abnormal cells in the bone marrow interferes with the production of functional white blood cells, red blood cells, and platelets. People with CBF-AML have a shortage of all types of mature blood cells: a shortage of white blood cells (leukopenia) leads to increased susceptibility to infections, a low number of red blood cells (anemia) causes fatigue and weakness, and a reduction in the amount of platelets (thrombocytopenia) can result in easy bruising and abnormal bleeding. Other symptoms of CBF-AML may include fever and weight loss. While acute myeloid leukemia is generally a disease of older adults, CBF-AML often begins in young adulthood and can occur in childhood. Compared to other forms of acute myeloid leukemia, CBF-AML has a relatively good prognosis: about 90 percent of individuals with CBF-AML recover from their disease following treatment, compared with 25 to 40 percent of those with other forms of acute myeloid leukemia. However, the disease recurs in approximately half of them after successful treatment of the initial occurrence.

MalaCards based summary : Core Binding Factor Acute Myeloid Leukemia, also known as cbf acute myeloid leukemia, is related to cytogenetically normal acute myeloid leukemia and mastocytosis. An important gene associated with Core Binding Factor Acute Myeloid Leukemia is KIT (KIT Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Fludarabine and Vidarabine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Core Binding Factor Acute Myeloid Leukemia

Diseases related to Core Binding Factor Acute Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 143)
# Related Disease Score Top Affiliating Genes
1 cytogenetically normal acute myeloid leukemia 30.3 WT1 FLT3 CEBPA
2 mastocytosis 30.2 KIT JAK2 FLT3 CBL
3 systemic mastocytosis 30.1 NRAS KIT JAK2
4 acute leukemia 28.6 WT1 RUNX1 MVP KRAS KIT JAK2
5 sarcoma 28.6 WT1 NRAS KRAS KIT JAK2 HRAS
6 leukemia 27.7 WT1 RUNX2 RUNX1 NRAS KRAS KIT
7 myeloid leukemia 27.4 WT1 RUNX2 RUNX1 NRAS KRAS KIT
8 myelodysplastic syndrome 26.9 WT1 RUNX1 NRAS KRAS KIT JAK2
9 leukemia, acute myeloid 26.5 WT1 RUNX2 RUNX1 NRAS MVP KRAS
10 breast cancer 26.2 WT1 RUNX2 NRAS MVP KRAS KIT
11 acute myeloblastic leukemia with maturation 10.5 KIT FLT3
12 thymoma, familial 10.4 KIT HRAS
13 signet ring basal cell carcinoma 10.4 KRAS HRAS
14 trachea carcinoma in situ 10.4 KRAS HRAS
15 co-trimoxazole allergy 10.4 KIT CSF3
16 nasal cavity adenocarcinoma 10.4 KRAS HRAS
17 ampulla of vater neoplasm 10.4 KRAS HRAS
18 periampullary adenoma 10.4 KRAS HRAS
19 eccrine papillary adenoma 10.4 KRAS HRAS
20 papillary adenoma 10.4 KRAS HRAS
21 8p11 myeloproliferative syndrome 10.4 RUNX1 KIT FLT3
22 myh-associated polyposis 10.4 KRAS HRAS
23 appendix adenocarcinoma 10.4 KRAS HRAS
24 mucinous lung adenocarcinoma 10.4 KRAS HRAS
25 pancreatic intraductal papillary-mucinous neoplasm 10.3 KRAS HRAS
26 sm-ahnmd 10.3 KIT JAK2
27 biliary tract benign neoplasm 10.3 KRAS HRAS
28 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 10.3 KIT JAK2
29 undifferentiated pleomorphic sarcoma 10.3 KRAS KIT
30 selection of therapeutic option in melanoma 10.3 NRAS KIT
31 acute erythroid leukemia 10.3 JAK2 CEBPA
32 testicular gonadoblastoma 10.3 WT1 KIT
33 ovarian mucinous neoplasm 10.3 KRAS HRAS
34 tumor of exocrine pancreas 10.3 KRAS HRAS
35 selection of therapeutic option in colorectal cancer 10.3 NRAS KRAS
36 pancreatic acinar cell adenocarcinoma 10.3 KRAS HRAS
37 appendix disease 10.3 KRAS HRAS
38 small intestine adenocarcinoma 10.3 KRAS HRAS
39 ovarian gonadoblastoma 10.3 WT1 KIT
40 hypereosinophilic syndrome, idiopathic 10.3 WT1 KIT
41 retinitis pigmentosa and erythrocytic microcytosis 10.3 JAK2 CSF3
42 in situ pulmonary adenocarcinoma 10.3 KRAS HRAS
43 uterine body mixed cancer 10.2 KRAS KIT HRAS
44 anus cancer 10.2 KRAS KIT HRAS
45 liver leiomyosarcoma 10.2 WT1 KIT
46 pyogenic granuloma 10.2 NRAS KRAS
47 neurofibromatosis, type iv, of riccardi 10.2 KRAS KIT HRAS
48 chromosomal triplication 10.2
49 trisomy 22 10.2
50 refractory anemia 10.2 RUNX1 CSF3

Graphical network of the top 20 diseases related to Core Binding Factor Acute Myeloid Leukemia:



Diseases related to Core Binding Factor Acute Myeloid Leukemia

Symptoms & Phenotypes for Core Binding Factor Acute Myeloid Leukemia

GenomeRNAi Phenotypes related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

26 (show top 50) (show all 67)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 10.87 CSF3 KRAS
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.87 CBL FLT3
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.87 KRAS
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-130 10.87 CBL
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.87 CBL CEBPA FLT3 KRAS WT1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.87 CBL CEBPA CSF3 NRAS
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.87 CBL
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.87 KRAS
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-171 10.87 FLT3
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-187 10.87 FLT3
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 10.87 KRAS
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 10.87 CBL CEBPA CSF3 NRAS CBFB
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.87 KRAS
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 10.87 KRAS
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.87 KRAS
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 10.87 NRAS
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.87 KRAS
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 10.87 CSF3
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 10.87 CBL
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-48 10.87 CEBPA
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.87 KRAS
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 10.87 CBFB
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.87 KRAS
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 10.87 CEBPA NRAS
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-79 10.87 CBFB
26 Decreased viability GR00055-A-2 10.35 HRAS KRAS
27 Decreased viability GR00106-A-0 10.35 KRAS
28 Decreased viability GR00173-A 10.35 FLT3
29 Decreased viability GR00221-A-1 10.35 CSF1R FLT3 HRAS KIT KRAS NRAS
30 Decreased viability GR00221-A-2 10.35 HRAS KRAS
31 Decreased viability GR00221-A-3 10.35 HRAS NRAS
32 Decreased viability GR00221-A-4 10.35 CSF1R FLT3
33 Decreased viability GR00301-A 10.35 KIT KRAS
34 Decreased viability GR00381-A-1 10.35 KRAS
35 Decreased viability GR00402-S-2 10.35 CSF1R FLT3 HRAS KIT KRAS NRAS
36 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.28 CBFB WT1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.28 FLT3
38 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.28 CBFB
39 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.28 FLT3
40 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.28 FLT3
41 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.28 CEBPA FLT3
42 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.28 CBFB CBL CEBPA FLT3 WT1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.28 FLT3
44 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.28 CBFB
45 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.28 CBL
46 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.28 CBL
47 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.28 WT1
48 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.28 FLT3
49 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.28 CBFB
50 Increased shRNA abundance (Z-score > 2) GR00366-A-180 10.28 CBFB FLT3

MGI Mouse Phenotypes related to Core Binding Factor Acute Myeloid Leukemia:

45 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.39 ABCG2 CBFB CBL CEBPA CSF1R FLT3
2 hematopoietic system MP:0005397 10.37 ABCG2 CBFB CBL CEBPA CSF1R CSF3
3 endocrine/exocrine gland MP:0005379 10.36 CBFB CBL CEBPA CSF1R FLT3 HRAS
4 homeostasis/metabolism MP:0005376 10.36 ABCG2 CBFB CBL CEBPA CSF1R FLT3
5 growth/size/body region MP:0005378 10.35 CBFB CBL CEBPA CSF1R FLT3 HRAS
6 immune system MP:0005387 10.34 ABCG2 CBFB CBL CEBPA CSF1R CSF3
7 cardiovascular system MP:0005385 10.32 CBFB CBL CEBPA HRAS JAK2 KIT
8 behavior/neurological MP:0005386 10.29 ABCG2 CBL CEBPA CSF1R HRAS JAK2
9 integument MP:0010771 10.29 ABCG2 CBFB CBL CEBPA CSF1R CSF3
10 mortality/aging MP:0010768 10.22 CBFB CBL CEBPA CSF1R FLT3 HRAS
11 craniofacial MP:0005382 10.17 CBFB CBL CSF1R HRAS KIT KRAS
12 liver/biliary system MP:0005370 10.17 ABCG2 CBFB CBL CEBPA JAK2 KIT
13 digestive/alimentary MP:0005381 10.1 CBFB CEBPA HRAS KIT KRAS NRAS
14 neoplasm MP:0002006 10.07 CBFB CEBPA FLT3 HRAS JAK2 KIT
15 no phenotypic analysis MP:0003012 10.06 CBFB CEBPA CSF1R FLT3 HRAS KIT
16 normal MP:0002873 10.03 ABCG2 CBFB CEBPA CSF1R HRAS JAK2
17 limbs/digits/tail MP:0005371 10 CBFB CBL CSF1R KIT KRAS NRAS
18 renal/urinary system MP:0005367 9.7 ABCG2 CEBPA CSF3 HRAS KIT KRAS
19 respiratory system MP:0005388 9.65 CBFB CBL CEBPA HRAS JAK2 KIT
20 skeleton MP:0005390 9.36 CBFB CBL CSF1R FLT3 HRAS JAK2

Drugs & Therapeutics for Core Binding Factor Acute Myeloid Leukemia

Drugs for Core Binding Factor Acute Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 31)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fludarabine Approved Phase 4 21679-14-1, 75607-67-9 30751
2
Vidarabine Approved, Investigational Phase 4 24356-66-9 32326 21704
3
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
4
Etoposide Approved Phase 2 33419-42-0 36462
5
Lenograstim Approved, Investigational Phase 2 135968-09-1
6
Mitoxantrone Approved, Investigational Phase 2 65271-80-9 4212
7
Busulfan Approved, Investigational Phase 2 55-98-1 2478
8
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
9
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
10
midostaurin Approved, Investigational Phase 2 120685-11-2 104937 9829523
11
Daunorubicin Approved Phase 2 20830-81-3 30323
12
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
13
Cytarabine Approved, Experimental, Investigational Phase 2 147-94-4, 65-46-3 6253
14
Alvocidib Experimental, Investigational Phase 2 146426-40-6, 131740-09-5 5287969
15 Staurosporine Experimental Phase 2 62996-74-1
16 Analgesics Phase 2
17 Adjuvants, Immunologic Phase 2
18 Etoposide phosphate Phase 2
19 Alkylating Agents Phase 2
20 Podophyllotoxin Phase 2 518-28-5
21 Anti-Bacterial Agents Phase 2
22 Protein Kinase Inhibitors Phase 2
23 Immunologic Factors Phase 2
24 Anti-Infective Agents Phase 2
25 Antibiotics, Antitubercular Phase 2
26 Topoisomerase Inhibitors Phase 2
27 Antiviral Agents Phase 2
28 Immunosuppressive Agents Phase 2
29 Antimetabolites Phase 2
30
Vitamin C Approved, Nutraceutical 50-81-7 5785 54670067
31 Aclacinomycins

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 Fludarabine and Cytarabine Versus High-dose Cytarabine in Consolidation Treatment of Core-bing Factor Acute Myeloid Leukemia: A Prospective, Multicenter, Randomized Study Recruiting NCT02926586 Phase 4 Fludarabine;Cytarabine
2 A Phase 3 Trial of Systematic Versus Response-adapted Timed-Sequential Induction in Patients With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Completed NCT00428558 Phase 3 Chemotherapy (DAUNORUBICINE-CYTARABINE);Chemotherapy (DAUNORUBICINE-CYTARABINE)
3 Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Recruiting NCT02013648 Phase 3 Dasatinib;Cytarabine;Daunorubicin;Idarubicin
4 Open-Label, Multicenter Phase Ib/IIa Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolida-tion Therapy as Well as in Maintenance Therapy in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Completed NCT00850382 Phase 1, Phase 2 Dasatinib;daunorubicin;Cytarabine
5 Phase II Study of Alvocidib (NSC 649890, Flavopiridol) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias Completed NCT00407966 Phase 2 alvocidib;cytarabine;mitoxantrone hydrochloride
6 Phase II Study of Maintenance Therapy With Decitabine (NSC #127716) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients With AML &lt; 60 Years Completed NCT00416598 Phase 2 Busulfan;Cytarabine;Daunorubicin Hydrochloride;Decitabine;Etoposide
7 Prospective Evaluation of a Continuation Therapy With Midostaurin in Adult Patients With Core-binding Factor Leukemia and Integrated Genetic Analysis: a Multi-center Phase II Study Recruiting NCT03686345 Phase 2 Midostaurin
8 Efficacy and Safety of Chidamide in CBF Leukemia Recruiting NCT03031262 Phase 1, Phase 2 Cytarabine;Chidamide
9 A Phase II Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy Plus Dasatinib (NSC #732517) and Continuation Therapy With Dasatinib Alone in Newly Diagnosed Patients With Core Binding Factor Acute Myeloid Leukemia (AML) Active, not recruiting NCT01238211 Phase 2 Cytarabine;Dasatinib;Daunorubicin Hydrochloride
10 Cytarabine Plus Continuous Infusion Daunorubicin Induction Therapy for Adults With Acute Myeloid Leukemia: A Feasibility Study With Cardiac MRI Monitoring Active, not recruiting NCT02971397 Phase 2 Cytarabine;Daunorubicin Hydrochloride
11 Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia: A Phase I Study (AflacLL1401) Withdrawn NCT02680951 Phase 1 Dasatinib;Fludarabine;Cytarabine;Idarubicin;Intrathecal (IT) cytarabine
12 Genome Wide SNP Array-based Approach to Detect Micro-cytogenetic Lesions and KIT Mutation to Improve Treatment Outcomes in Patients With Core-binding Factor Positive Acute Myeloid Leukemia Unknown status NCT01066286
13 The Efficiency of CAMS-2016 Trial for the Newly Diagnosed Pediatric Acute Myeloid Leukemia: A Prospective Single Centre Trial From China Recruiting NCT03173612 Dasatinib
14 Phase 2 Study of Autologous Hematopoietic Cell Transplantation for Core-binding Factor Positive Acute Myeloid Leukemia in the First Complete Remission Recruiting NCT01050036

Search NIH Clinical Center for Core Binding Factor Acute Myeloid Leukemia

Genetic Tests for Core Binding Factor Acute Myeloid Leukemia

Anatomical Context for Core Binding Factor Acute Myeloid Leukemia

MalaCards organs/tissues related to Core Binding Factor Acute Myeloid Leukemia:

40
Myeloid, Bone, Bone Marrow, Thyroid, Appendix, Lung, Skin

Publications for Core Binding Factor Acute Myeloid Leukemia

Articles related to Core Binding Factor Acute Myeloid Leukemia:

(show top 50) (show all 139)
# Title Authors PMID Year
1
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. 61
31899799 2020
2
Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia. 61
31896684 2020
3
[The impact of KIT and other concomitant gene mutations on the prognoses of patients with core-binding factor acute myeloid leukemia]. 61
32008291 2020
4
Excellent outcome after consolidation with autologous transplantation in patients with core binding factor acute myeloid leukemia. 61
31796871 2019
5
[A multivariate model for predicting induction response and prognosis in core binding factor acute myeloid leukemia]. 61
31665853 2019
6
N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells. 61
31484543 2019
7
Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. 61
31439677 2019
8
Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemia. 61
31311917 2019
9
[Characterization of mutational pattern of patients with core-binding factor acute myeloid leukemia]. 61
31302905 2019
10
Myeloid translocation gene CBFA2T3 directs a relapse gene program and determines patient-specific outcomes in AML. 61
31040112 2019
11
Different prognostic effects of core-binding factor positive AML with Korean AML registry data. 61
30758645 2019
12
The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia. 61
30089916 2019
13
[Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia]. 61
30704229 2019
14
Inhibition of N822K T>A mutation-induced constitutive c-KIT activation in AML cells triggers apoptotic and autophagic pathways leading to death. 61
31217744 2019
15
Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study. 61
30082223 2018
16
Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit). 61
30117318 2018
17
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. 61
29991495 2018
18
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial. 61
29720733 2018
19
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. 61
29692343 2018
20
Evolution of a chemosensitive core-binding factor AML into an aggressive leukemia with eosinophilic differentiation. 61
29950292 2018
21
Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia. 61
29705537 2018
22
Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients. 61
29500710 2018
23
Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate-/high-dose cytarabine. 61
29719925 2018
24
KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia. 61
28792268 2018
25
SNP-array lesions in core binding factor acute myeloid leukemia. 61
29464086 2018
26
Detection of KIT mutations in core binding factor acute myeloid leukemia. 61
30112273 2018
27
[Molecular pathogenesis and treatment of core binding factor-acute myeloid leukemia]. 61
30305502 2018
28
Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia. 61
29107583 2018
29
Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF-AML) - a single center analysis. 61
27597292 2017
30
Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R study. 61
28233452 2017
31
D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations. 61
28762080 2017
32
Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet? 61
28654205 2017
33
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. 61
28494506 2017
34
Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia. 61
29071049 2017
35
Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. 61
28556489 2017
36
Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia. 61
28439893 2017
37
D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia. 61
28506695 2017
38
Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia. 61
27843138 2017
39
Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia. 61
28368672 2017
40
Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Systematic Review. 61
27613372 2017
41
Frontline treatment of acute myeloid leukemia in adults. 61
28109402 2017
42
Genetic abnormalities in core binding factor acute myeloid leukemia. 61
28883285 2017
43
Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome. 61
27391574 2016
44
Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. 61
27298396 2016
45
RNA-sequencing analysis of core binding factor AML identifies recurrent ZBTB7A mutations and defines RUNX1-CBFA2T3 fusion signature. 61
26968532 2016
46
Comprehensive mutational profiling of core binding factor acute myeloid leukemia. 61
26980726 2016
47
Stem Cell Modeling of Core Binding Factor Acute Myeloid Leukemia. 61
26880987 2016
48
Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. 61
26771376 2016
49
Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia. 61
26771813 2016
50
Additional chromosomal abnormalities in core-binding factor acute myeloid leukemia. 61
26681050 2015

Variations for Core Binding Factor Acute Myeloid Leukemia

Expression for Core Binding Factor Acute Myeloid Leukemia

Search GEO for disease gene expression data for Core Binding Factor Acute Myeloid Leukemia.

Pathways for Core Binding Factor Acute Myeloid Leukemia

Pathways related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 97)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 NRAS MVP KRAS KIT JAK2 HRAS
2
Show member pathways
13.84 NRAS KRAS KIT JAK2 HRAS FLT3
3
Show member pathways
13.7 NRAS KRAS KIT JAK2 HRAS FLT3
4
Show member pathways
13.57 NRAS KRAS KIT JAK2 HRAS FLT3
5
Show member pathways
13.33 NRAS KRAS KIT JAK2 HRAS CSF3
6
Show member pathways
13.31 NRAS KRAS KIT JAK2 HRAS FLT3
7
Show member pathways
13.24 TLE1 NRAS KRAS KIT HRAS FLT3
8
Show member pathways
13.22 NRAS KRAS KIT JAK2 HRAS FLT3
9
Show member pathways
13.08 NRAS KRAS KIT JAK2 HRAS CSF1R
10
Show member pathways
12.92 NRAS KRAS JAK2 HRAS CBL
11
Show member pathways
12.84 NRAS KRAS JAK2 HRAS CBL
12
Show member pathways
12.84 NRAS KRAS KIT JAK2 HRAS FLT3
13
Show member pathways
12.79 NRAS KRAS KIT JAK2 HRAS CBL
14
Show member pathways
12.76 NRAS KRAS KIT HRAS CBL
15 12.75 NRAS KRAS KIT HRAS FLT3 CSF1R
16
Show member pathways
12.71 NRAS KRAS KIT HRAS FLT3 CSF1R
17
Show member pathways
12.65 NRAS KRAS JAK2 HRAS CBL
18
Show member pathways
12.63 NRAS KRAS JAK2 HRAS CBL
19
Show member pathways
12.61 NRAS KRAS JAK2 HRAS
20
Show member pathways
12.6 NRAS KRAS HRAS CBL
21 12.59 RUNX1 KIT JAK2 CEBPA CBL
22
Show member pathways
12.58 NRAS KRAS HRAS CBL
23
Show member pathways
12.57 TLE1 RUNX2 JAK2 CBL
24
Show member pathways
12.54 NRAS KRAS HRAS CBL
25
Show member pathways
12.52 NRAS KRAS JAK2 HRAS CBL
26
Show member pathways
12.51 NRAS KRAS HRAS CBL
27
Show member pathways
12.5 NRAS KRAS JAK2 HRAS CBL
28
Show member pathways
12.45 NRAS KRAS HRAS CBL
29
Show member pathways
12.44 NRAS KRAS HRAS CBL
30
Show member pathways
12.44 NRAS KRAS KIT HRAS
31
Show member pathways
12.43 JAK2 HRAS CEBPA CBL
32
Show member pathways
12.37 NRAS KRAS HRAS CBL
33
Show member pathways
12.37 NRAS KRAS HRAS FLT3 CBL
34
Show member pathways
12.36 RUNX1 NRAS KRAS KIT HRAS FLT3
35 12.34 NRAS KRAS HRAS CBL
36
Show member pathways
12.34 NRAS KRAS JAK2 HRAS
37
Show member pathways
12.31 NRAS KRAS HRAS CBL
38
Show member pathways
12.27 NRAS KRAS KIT HRAS FLT3 CSF1R
39
Show member pathways
12.25 NRAS KRAS JAK2 HRAS
40
Show member pathways
12.24 NRAS KRAS HRAS CSF1R
41 12.23 KRAS JAK2 HRAS CBL
42
Show member pathways
12.22 KIT JAK2 HRAS CBL
43
Show member pathways
12.18 NRAS KRAS HRAS CBL
44
Show member pathways
12.18 NRAS KRAS JAK2 HRAS FLT3 CBL
45 12.13 NRAS KRAS JAK2 HRAS
46
Show member pathways
12.11 NRAS KRAS JAK2 HRAS
47
Show member pathways
12.1 NRAS KRAS JAK2 HRAS
48
Show member pathways
12.1 KRAS JAK2 HRAS CBL
49
Show member pathways
12.08 NRAS KRAS HRAS CBL
50 12.05 KIT JAK2 FLT3 CSF1R CBL

GO Terms for Core Binding Factor Acute Myeloid Leukemia

Cellular components related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.85 WT1 TLE1 RUNX2 RUNX1 JAK2 HRAS
2 membrane raft GO:0045121 9.26 KRAS JAK2 CBL ABCG2
3 core-binding factor complex GO:0016513 8.62 RUNX1 CBFB

Biological processes related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.13 TLE1 NRAS KRAS KIT JAK2 HRAS
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.09 WT1 RUNX2 RUNX1 HRAS CSF3 CEBPA
3 negative regulation of cell proliferation GO:0008285 9.97 WT1 JAK2 HRAS CSF1R CEBPA
4 positive regulation of gene expression GO:0010628 9.93 WT1 TLE1 RUNX2 KRAS KIT HRAS
5 positive regulation of cell migration GO:0030335 9.92 KIT JAK2 HRAS CSF1R
6 protein autophosphorylation GO:0046777 9.86 KIT JAK2 FLT3 CSF1R
7 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.85 KIT FLT3 CSF1R
8 positive regulation of MAPK cascade GO:0043410 9.85 KIT HRAS FLT3
9 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.85 NRAS KRAS HRAS
10 positive regulation of DNA-binding transcription factor activity GO:0051091 9.84 KIT JAK2 CSF3
11 male gonad development GO:0008584 9.83 WT1 KIT CBL
12 peptidyl-tyrosine phosphorylation GO:0018108 9.8 KIT JAK2 FLT3 CSF1R
13 MAPK cascade GO:0000165 9.8 NRAS KRAS KIT JAK2 HRAS FLT3
14 Ras protein signal transduction GO:0007265 9.79 NRAS KRAS HRAS
15 hematopoietic progenitor cell differentiation GO:0002244 9.77 KIT FLT3 CSF1R
16 cellular response to cytokine stimulus GO:0071345 9.76 FLT3 CSF3 CSF1R
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.71 KIT JAK2 FLT3 CSF1R
18 cell maturation GO:0048469 9.69 RUNX2 CEBPA CBFB
19 regulation of keratinocyte differentiation GO:0045616 9.67 RUNX1 CBFB
20 positive regulation of MAP kinase activity GO:0043406 9.67 KRAS KIT HRAS FLT3
21 regulation of regulatory T cell differentiation GO:0045589 9.66 RUNX1 CBFB
22 regulation of intracellular estrogen receptor signaling pathway GO:0033146 9.66 RUNX1 CBFB
23 mast cell degranulation GO:0043303 9.65 KIT CBL
24 regulation of bicellular tight junction assembly GO:2000810 9.65 RUNX1 CBFB
25 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.65 KIT JAK2 FLT3 CSF3 CBL
26 positive regulation of phospholipase C activity GO:0010863 9.64 KIT HRAS
27 regulation of B cell receptor signaling pathway GO:0050855 9.64 RUNX1 CBFB
28 regulation of myeloid cell differentiation GO:0045637 9.63 RUNX1 CBFB
29 granulocyte differentiation GO:0030851 9.63 CSF3 CEBPA
30 lymphocyte differentiation GO:0030098 9.62 FLT3 CBFB
31 regulation of cytokine-mediated signaling pathway GO:0001959 9.61 RUNX1 CBFB
32 interleukin-6-mediated signaling pathway GO:0070102 9.61 JAK2 CEBPA CBL
33 response to isolation stress GO:0035900 9.59 KRAS HRAS
34 myeloid progenitor cell differentiation GO:0002318 9.57 KIT FLT3
35 positive regulation of cell proliferation GO:0008284 9.56 RUNX2 KRAS KIT JAK2 HRAS FLT3
36 hemopoiesis GO:0030097 9.55 RUNX2 RUNX1 KIT FLT3 CSF1R
37 positive regulation of CD8-positive, alpha-beta T cell differentiation GO:0043378 9.54 RUNX1 CBFB
38 negative regulation of CD4-positive, alpha-beta T cell differentiation GO:0043371 9.52 RUNX1 CBFB
39 cytokine-mediated signaling pathway GO:0019221 9.23 KRAS KIT JAK2 FLT3 CSF3 CSF1R

Molecular functions related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.16 WT1 TLE1 RUNX2 RUNX1 NRAS MVP
2 ATP binding GO:0005524 9.95 RUNX2 RUNX1 KIT JAK2 FLT3 CSF1R
3 transcription regulatory region DNA binding GO:0044212 9.67 WT1 RUNX2 RUNX1 CEBPA
4 GDP binding GO:0019003 9.5 NRAS KRAS HRAS
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 KIT FLT3 CSF1R
6 protein tyrosine kinase activity GO:0004713 9.26 KIT JAK2 FLT3 CSF1R
7 nucleotide binding GO:0000166 9.1 NRAS KRAS KIT JAK2 HRAS FLT3

Sources for Core Binding Factor Acute Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....